Pancreatic Cancer Research

ResearcherUniversidad San Pablo CEUActive in the last 2 years

Antonio Cubillo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7511-7121; OpenAlex author ID A5000928175. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 3 papers

Papers 15

  1. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  2. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With N… Last author DOI 10.1097/coc.0000000000001253↗
  3. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  4. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  5. Real-world effectiveness and safety of second- or third-line pegylated liposomal irinotecan plus 5-fluorouracil and folinic acid in pancreatic ductal adenocarc… Last author DOI 10.1177/17588359241309828↗
  6. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world stud… Co-author DOI 10.1186/s12885-023-11377-1↗
  7. A prospective observational study of the clinical and pathological impact of stereotactic body radiotherapy (SBRT) as a neoadjuvant strategy of chemoradiation … Co-author DOI 10.1007/s12094-020-02287-w↗
  8. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. First author DOI 10.1016/j.ejca.2018.09.029↗
  9. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. Co-author DOI 10.1002/ijc.31603↗
  10. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2017.08.003↗
  11. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based … Co-author DOI 10.1038/bjc.2017.67↗
  12. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  13. Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'. Co-author DOI 10.1038/bjc.2014.129↗
  14. A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Co-author DOI 10.1007/s10637-012-9822-x↗
  15. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/bjc.2013.415↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 4 shared papers, 2018–2026 · strength 0.70
  2. Rafael Álvarez-Gallego · 3 shared papers, 2017–2026 · strength 0.52
  3. Yolanda Quijano · 6 shared papers, 2013–2026 · strength 0.49
  4. Emilio Vicente · 6 shared papers, 2013–2026 · strength 0.49
  5. Berta Laquente · 1 shared paper, 2026 · strength 0.25
  6. Florian Castet · 1 shared paper, 2026 · strength 0.25
  7. Juli Busquets · 1 shared paper, 2026 · strength 0.25
  8. Ismael Ghanem · 1 shared paper, 2025 · strength 0.21
  9. Joaquina Martínez-Galán · 1 shared paper, 2025 · strength 0.21
  10. Roberto Pazo-Cid · 1 shared paper, 2025 · strength 0.21
  11. Carlos Plaza · 4 shared papers, 2013–2020 · strength 0.21
  12. Daniel H. Palmer · 1 shared paper, 2023 · strength 0.17
  13. Thomas Theodor Werner Seufferlein · 1 shared paper, 2023 · strength 0.17
  14. Julien Taı̈eb · 1 shared paper, 2023 · strength 0.17
  15. Gerald W. Prager · 1 shared paper, 2023 · strength 0.17
  16. Michele Reni · 1 shared paper, 2023 · strength 0.17
  17. Manuel M. Hidalgo · 4 shared papers, 2013–2018 · strength 0.17
  18. Rafael Álvarez · 3 shared papers, 2013–2020 · strength 0.15
  19. Floris A. de Jong · 2 shared papers, 2017–2019 · strength 0.14
  20. Jean‐Frédéric Blanc · 2 shared papers, 2017–2019 · strength 0.14
  21. Li‐Tzong Chen · 2 shared papers, 2017–2019 · strength 0.14
  22. Jens Thomas Siveke · 2 shared papers, 2017–2019 · strength 0.14
  23. Davide Melisi · 2 shared papers, 2017–2019 · strength 0.14
  24. Richard A Hubner · 2 shared papers, 2017–2019 · strength 0.14
  25. Andrea Wang‐Gillam · 2 shared papers, 2017–2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.